Anti-epidermal growth factor receptor therapy concurrently with induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma

Hao Peng1 | Ling-Long Tang1 | Xu Liu1 | Lei Chen1 | Wen-Fei Li1 | Yan-Ping Mao1 | Yuan Zhang1 | Li-Zhi Liu2 | Li Tian2 | Ying Guo3 | Ying Sun1 | Jun Ma1

1State Key Laboratory of Oncology in South China, Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
2State Key Laboratory of Oncology in South China, Imaging Diagnosis and Interventional Center, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
3State Key Laboratory of Oncology in South China, Department of Clinical Trials Center, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China

Correspondence
Jun Ma, State Key Laboratory of Oncology in South China, Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
Email: majun2@mail.sysu.edu.cn

Funding information
National Science & Technology Pillar Program during the Twelfth Five-year Plan Period (2014BAI09B10); Natural Science Foundation of Guangdong Province (2017A030312003); National Natural Science Foundation of China (81572658); Program of Introducing Talents of Discipline to Universities (B14035); Innovation Team Development Plan of the Ministry of Education (No. IRT_17R110).

Little is known about the efficacy and toxicity of anti-epidermal growth factor receptor therapy concurrently with induction chemotherapy (IC) in locoregionally advanced nasopharyngeal carcinoma (LA-NPC). The present study aimed to address this question. We identified 2848 patients with newly diagnosed LA-NPC receiving IC between January 2012 and May 2015. The propensity score matching (PSM) method was used to balance various factors and to match patients. Survival outcomes and toxicities between different groups were compared. In total, 596 patients were selected at a 1:3 ratio, with 149 in the IC + CTX/NTZ group and 447 in the IC alone group. The 3-year disease-free survival, overall survival, distant metastasis-free survival and locoregional relapse-free survival rates for IC + CTX/NTZ vs IC alone were 84.3% vs 75.2% \((P = 0.059)\), 94.0% vs 87.9% \((P = 0.053)\), 88.0% vs 84.9% \((P = 0.412)\) and 93.3% vs 88.2% \((P = 0.242)\). Multivariate analysis established a treatment group (IC vs IC + CTX/NTZ) as a prognostic predictor for DFS (hazard ratio [HR], 1.497; 95% confidence interval [CI], 1.016-2.206; \(P = 0.041)\) and OS (HR, 1.984; 95%, CI, 1.023-3.848; \(P = 0.043)\). Grade 3-4 skin reaction (15.4% vs 0.4%, \(P < 0.001)\) and mucositis (10.1% vs 2.7%, \(P < 0.001)\) were more common in the IC + CTX/NTZ group than in the IC alone group. Our findings suggested that CTX/NTZ in combination with IC may be a more effective and promising strategy for patients with LA-NPC treated with intensity-modulated radiotherapy.

KEYWORDS
cetuximab, induction chemotherapy, intensity-modulated radiotherapy, nasopharyngeal carcinoma, nimotuzumab

1 INTRODUCTION

Nasopharyngeal carcinoma (NPC) is a special type of head and neck malignancy because of its unbalanced geographic distribution and treatment modality. There were 86 700 new cases reported worldwide in 2012, with the highest incidence in South China.\(^1\) Unlike other head and neck cancers, radiotherapy (RT) is the primary and only cure for non-disseminated disease as a result of the anatomic constraint and sensitivity to radiation. Control of early stage disease with RT alone or chemoradiation is usually excellent; however,
management of locoregionally advanced NPC (LA-NPC) remains unsatisfactory, with a 5-year overall survival (OS) of 67%-77%.20

Unfortunately, more than 70% of newly cases were locoregionally advanced disease at initial diagnosis.3 Currently, concurrent chemoradiation (CCRT) is the main standard care for LA-NPC. Although local and regional control has improved greatly, the rate of distant metastasis after treatment remains high and is the main source of treatment failure.4 Therefore, identification of novel and effective therapeutic strategies is urgent and crucial for clinicians.

Epidermal growth factor receptor (EGFR), a transmembrane protein highly expressed in most human epithelial malignancies,5 is a promising therapeutic target in oncology for its correlation with aggressive phenotype, treatment resistance and poor prognosis.6,7 EGFR is also highly expressed in NPC8 and numerous studies have evaluated the efficacy of anti-EGFR targeted therapy.9-15 Cetuximab (CTX) or nimotuzumab (NTZ) (anti-EGFR monoclonal antibodies) concurrent with RT could achieve comparable outcomes compared with standard cisplatin-RT.12,14 When combined with CCRT, different results were produced. You et al13 and Xia et al11 revealed that CTX/NTZ additional to CCRT was more effective than CCRT alone, while Li et al10 did not identify any difference. Regardless of the controversial efficacy, CTX/NTZ significantly increased the incidence of acute mucositis and acneiform rash during RT,10,12 resulting in poor quality of life or even disruption of RT. It seems that anti-EGFR therapy concurrent with RT may not be the best choice.

Induction chemotherapy (IC), given before RT, has been proven as a promising treatment in LA-NPC for its satisfactory compliance and efficacy in reducing distant metastasis.16-20 NTZ in combination with IC may further reduce distant metastasis and improve survival outcomes. However, no relative study to date has been carried out. Given this concern, we initiated this retrospective study to evaluate the efficacy of CTX/NTZ additional to CCRT was more effective than CCRT alone.

2.1 Study patient

We identified 14,684 patients with newly diagnosed NPC on the big-data, intelligence database platform (YiduCloud Technology, Beijing, China) at Sun Yat-sen University Cancer Center between January 2012 and May 2015. This intelligence platform has been described in detail previously.21 Inclusion criteria for this study were as follows: (i) stage III-IVB disease; (ii) age ≥ 18 years; (iii) Karnofsky performance score (KPS) ≥ 70; (iv) without prior malignancies; (v) receiving IC followed by CCRT or RT alone; (vi) concurrent chemotherapy, if any, should be single-agent cisplatin; and (vii) receiving intensity-modulated radiotherapy (IMRT).

2.2 Pre-treatment staging workup

Conventional staging workup in our center included physical examination of head and neck, direct nasopharyngoscopy, chest radiography or computed tomography (CT), MRI of head and neck, abdominal sonography, whole-body bone scan and blood profiling. PET-CT would also be recommended for patients with advanced N (N2-3) category. Magnetic resonance (MR) or CT scans of patients were reviewed separately by 2 radiologists employed at our center with more than 10-years’ experience, and any discrepancy was resolved by consensus. Tumor stage was determined according to the 8th edition of the International Union against Cancer/American Joint Committee on Cancer (UICC/AJCC) manual.

2.3 Treatment

All patients received radical IMRT at our center using the simultaneous integrated boost (SIB) technique as previously described.18,22 Briefly, the prescribed radiation doses were: 66-70 Gy at 2.12-2.23 Gy/fraction to the planning target volume (PTV) of nasopharyngeal gross tumor volume (GTV), 64-70 Gy to the PTV of GTV of metastatic lymph nodes, 60-63 Gy to the PTV of high-risk clinical target volume, and 50-56 Gy to the PTV of low-risk clinical target volume.

Induction chemotherapy mainly consisted of cisplatin-based regimens including docetaxel with cisplatin (TP), fluorouracil with cisplatin (PF), or docetaxel plus cisplatin with fluorouracil (TPF) every 3 weeks for 2-4 cycles. Concurrent chemotherapy was tri-weekly cisplatin or weekly cisplatin.

Cetuximab was delivered concurrently with IC at a dose of 400 mg/m2 every 3 weeks, which was diluted in 250 mL saline and intravenously infused over 1 hour. Intravenous NTZ was administered at a dose of 200 mg during IC every 3 weeks. Detailed treatment information is presented in Data S1.

2.4 Clinical endpoints and statistical analysis

Study endpoints included disease-free survival (DFS, defined as the time from diagnosis to disease progression or death from any cause); OS (time from diagnosis to death from any cause), distant metastasis-free survival (DMFS, time from diagnosis to first distant metastasis) and locoregional relapse-free survival (LRRFS, time from diagnosis to local or regional recurrence or both). Tumor response to IC was evaluated based on Response Evaluation Criteria in Solid Tumors.23 Acute toxicities during IC were graded according to the Common Terminology Criteria for Adverse Events (version 3.0).

The chi-squared test was adopted to compare categorical variables and the Mann-Whitney test for continuous variables. Propensity score matching (PSM) was computed by logistic regression for each patient at a 1:1 ratio to balance various factors, including gender, age, lactate dehydrogenase (LDH), IC regimen and cycle, tumor stage and cumulative cisplatin dose (CCD) during RT.24 The caliper was set at 0.01 to achieve a satisfactory match. Survival outcomes were calculated using the Kaplan-Meier method and compared by log-rank test. The multivariate cox proportional hazards model was
used to estimate hazard ratios (HR), 95% confidence intervals (CI) and independent prognostic factors.

3 | RESULTS

3.1 | Patient baseline characteristics

A flow chart of patient inclusion is presented in Figure 1. In total, 2848 patients were eligible for our study (Table S1). An eventual 596 patients were selected by PSM, with 149 in the IC + CTX/NTZ group and 447 in the IC alone group. Baseline characteristics are summarized in Table 1. The median age for the whole cohort is 43 years, and the male-to-female ratio is 3.8:1. Host and tumor-related factors were well balanced between the IC plus CTX/NTZ and IC alone groups. Moreover, patients in these 2 groups had similar pre-treatment imaging stage workups (Table S2) and chemotherapy intensity (Table S3).

Among the 149 patients receiving anti-EGFR therapy, 56 (37.6%) received CTX and the remaining 93 (62.4%) patients received NTZ. Detailed information on dose and cycle of CTX/NTZ is shown in Table S4. More patients in the NTZ arm received 2 cycles than those in the CTX arm ($P = .001$). No dose reduction occurred in the 2 arms.

3.2 | Short-term efficacy after induction chemotherapy

Twenty-five patients with N0 category were not available for regional response evaluation, with 7 (4.7%) in the IC + CTX/NTZ group and 18 (4.0%) in the IC group. After the completion of IC, 17 (11.4%), 121 (81.2%) and 11 (7.4%) in the IC + CTX/NTZ group, and 35 (7.8%), 364 (81.4%) and 48 (10.7%) in the IC alone group achieved complete response (CR), partial response (PR) and stable disease (SD), respectively ($P = .233$). No patient had progressive disease (PD) in either group. Table S5 provides information on tumor response.

3.3 | Long-term outcome analysis

Up to the last visit (30 September 2017), the median follow-up duration was 40.5 months (range 1.27-64.8). Overall, 26 patients (17.4%) in the IC + CTX/NTZ group and 110 patients (24.6%) in IC alone group experienced treatment failure ($P = .071$). No treatment-related death occurred. Three-year DFS, OS, DMFS and LRRFS rates for the whole cohort were 77.3%, 89.4%, 85.7% and 89.5%, respectively.

The 3-year DFS, OS, DMFS and LRRFS rates for the IC + CTX/NTZ group vs the IC alone group were 84.3% vs 75.2% ($P = .059$), 94.0% vs 87.9% ($P = .053$), 88.0% vs 84.9% ($P = .412$) and 93.3% vs 88.2% ($P = .242$, Figure 2). After adjusting for various prognostic factors, the treatment group (IC vs IC + CTX/NTZ) was a significantly prognostic predictor for DFS (HR, 1.497; 95% CI, 1.016-2.206; $P = .041$) and OS (HR, 1.497; 95% CI, 1.016-2.206; $P = .043$) but not for DMFS (HR, 1.198; 95% CI, 0.773-2.735; $P = .246$) and LRRFS (HR, 1.454; 95% CI, 0.773-2.735; $P = .246$; Table 2).

3.4 | Subgroup analysis

We conducted further exploratory analysis according to tumor stage as the multivariate analysis indicated it was an independent prognostic factor. In patients with stage III disease, 284 patients were selected (Table S6). Univariate analysis found that the IC + CTX/NTZ group achieved better 3-year DFS and OS but the difference was not significant (Figure S1). When entered into the multivariate analysis, no significant survival difference between IC + CTX/NTZ and IC alone groups were observed (Table S7). With regard to the 312 patients selected by PSM (Table S8), similar results were produced for univariate (Figure S2) and multivariate analyses (Table S9).

3.5 | Grade 3-4 toxicities

The acute toxicity profile during IC and radiotherapy was evaluated between the 2 groups and is presented in Tables 3 and S10. Generally, patients in the IC + CTX/NTZ group suffered more grade 3-4 toxicities.
toxic events compared with those in the IC alone group (52.3% vs 42.7%, \( P = .041 \)) during IC, and a significant difference was mainly observed in anti-EGFR therapy-related skin reaction (15.4% vs 0.4%, \( P < .001 \)) and mucositis (10.1% vs 2.7%, \( P < .001 \)). Hematological and gastrointestinal adverse events were similar between the 2 groups (all rates, \( P > .005 \)). No significant difference with regard to toxicities during radiotherapy was observed between these 2 groups.

**DISCUSSION**

Advanced disease has always been a difficult issue, not only in relation to NPC management but also in many other cancers because prognosis for this subgroup is poor. Therefore, identification and establishment of a novel and effective treatment is urgent and necessary. As far as we know, our study is the first to evaluate the efficacy and safety of anti-EGFR therapy (CTX or NTZ) in combination with induction chemotherapy in LA-NPC treated by IMRT. We found that additional CTX/NTZ to IC could prolong DFS and OS, but not DMFS and LRRFS. Anti-EGFR therapy-related toxicities of skin and mucositis were also more common in the IC + CTX/NTZ group.

With the wide application of IMRT in NPC, local and regional control has improved greatly and distant metastasis has become the main failure pattern.\(^4,25\) Although CCRT is effective, it may be not powerful enough to reduce distant metastasis for advanced disease.\(^26\) You et al\(^13\) and Li et al\(^10\) enhanced the treatment intensity during concurrent phase by adding CTX/NTZ to standard concomitant cisplatin. However, the efficacy may be unsatisfactory. At the same time, adverse events significantly increased. Possibly, concurrent administration of anti-EGFR therapy with cisplatin is a feasible strategy, but not the best. Additional cycles of chemotherapy like IC or adjuvant chemotherapy (AC) to CCRT may be a better choice. Actually, IC followed by CCRT is a preferable treatment modality for its better compliance and excellent efficacy\(^16,17,19\) compared with CCRT with AC. In our current study, we provide a new insight in improving survival outcomes by enhancing the treatment during induction phase. By adding CTX/NTZ to IC, DFS and OS were significantly improved, indicating this is a promising treatment modality.

Epidermal growth factor receptor on tumor cells has been established as a factor predicting treatment resistance and poor

**TABLE 1** Baseline characteristics of the selected 596 patients with stage III-IVB nasopharyngeal carcinoma receiving IC

| Characteristics | IC + CXT/NTZ (N = 149) | IC (N = 447) | P-value^a |
|-----------------|-------------------------|-------------|-----------|
| Gender          |                         |             |           |
| Male            | 116 (77.9)              | 355 (79.4)  | .684      |
| Female          | 33 (22.1)               | 92 (20.6)   |           |
| Age (years)     |                         |             |           |
| Median (IQR)    | 42 (36-51)              | 44 (36-51)  | .422      |
| Smoking         |                         |             |           |
| Yes             | 57 (38.3)               | 175 (39.1)  | .846      |
| No              | 92 (61.7)               | 272 (60.9)  |           |
| Drinking        |                         |             |           |
| Yes             | 30 (20.1)               | 89 (19.9)   | .845      |
| No              | 119 (79.9)              | 357 (80.1)  |           |
| Family history of cancer |               |             |           |
| Yes             | 47 (31.5)               | 111 (24.8)  | .205      |
| No              | 102 (68.5)              | 334 (75.2)  |           |
| LDH (U/L)       |                         |             |           |
| Median (IQR)    | 175 (154-216)           | 185 (160-215)| .155     |
| T category^b    |                         |             |           |
| T1              | 6 (4.0)                 | 12 (2.7)    | .163      |
| T2              | 7 (4.7)                 | 47 (10.5)   |           |
| T3              | 81 (54.4)               | 228 (51.0)  |           |
| T4              | 55 (36.9)               | 160 (35.8)  |           |
| N category^b    |                         |             |           |
| N0              | 7 (4.7)                 | 18 (4.0)    | .966      |
| N1              | 49 (32.9)               | 141 (31.6)  |           |
| N2              | 61 (40.9)               | 187 (41.8)  |           |
| N3              | 32 (21.5)               | 101 (22.6)  |           |
| Overall stage^b |                         |             |           |
| III             | 71 (47.7)               | 207 (46.3)  | .776      |
| IVA-B           | 78 (52.3)               | 240 (53.7)  |           |
| IC regimen      |                         |             |           |
| TPF             | 50 (33.6)               | 149 (33.3)  | .998      |
| PF              | 45 (30.2)               | 136 (30.4)  |           |
| TP              | 54 (36.2)               | 162 (36.3)  |           |
| IC cycle        |                         |             |           |
| Two             | 100 (67.1)              | 290 (64.9)  | .811      |
| Three           | 43 (28.9)               | 134 (30.0)  |           |
| Four            | 6 (4.0)                 | 23 (5.1)    |           |
| Concurrent chemotherapy |           |             |           |
| Yes             | 137 (91.9)              | 400 (89.5)  | .384      |
| No              | 12 (8.1)                | 47 (10.5)   |           |

^a^P-values were calculated using the chi-squared-test for categorical variables and the Mann-Whitney test for continuous variables.

^b^According to the 8th edition of the International Union against Cancer/ American Joint Committee on Cancer (UICC/AJCC) system.

P < .001 and mucositis (10.1% vs 2.7%, \( P < .001 \)). Hematological and gastrointestinal adverse events were similar between the 2 groups (all rates, \( P > .005 \)). No significant difference with regard to toxicities during radiotherapy was observed between these 2 groups.

**TABLE 1** (Continued)

| Characteristics | IC + CXT/NTZ (N = 149) | IC (N = 447) | P-value^a |
|-----------------|-------------------------|-------------|-----------|
| CCD (mg/m^2)    |                         |             |           |
| Median (range)  | 160 (0-300)             | 160 (0-300) | .118      |
| ≥200            | 41 (27.5)               | 90 (20.1)   |           |
| <200            | 108 (72.5)              | 357 (79.9)  |           |

CCD, cumulative cisplatin dose during radiotherapy; CXT, cetuximab; IC, induction chemotherapy; IQR, interquartile; LDH, lactate dehydrogenase; NTZ, nimotuzumab.

1612 | PENG ET AL.
prognosis, making anti-EGFR a potential and promising treatment. Antitumor efficacy of CTX in combination with conventional chemotherapy has been proven in various EGFR-expressing malignancies like colorectal cancer, head and neck cancers and recurrent NPC. In recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), CTX combined with fluorouracil-cisplatin chemotherapy achieved significantly better DFS and OS compared with fluorouracil-cisplatin alone when given as the first-line therapy. It seems that CTX adds additional anti-tumor efficacy to previously administered chemotherapy and thereby improved efficacy. Taken this, it's reasonable to speculate that CTX/NTZ adds additional efficacy to induction chemotherapy in NPC. Therefore, CTX/NTZ in combination with IC could achieve better DFS and OS than IC alone in our study.

With regard to the primary analysis, DFS and OS were significantly improved in IC + CTX/NTZ group while DMFS and LRRFS was not. The significantly improved OS and DFS may originate from combined enhancement of DMFS and LRRFS although DMFS alone or LRRFS alone was not significantly improved. When subgroup analysis was conducted according to tumor stage (III or IV), survival outcomes were not significantly difference between IC + CTX/NTZ and IC alone groups in both subgroups. However, survival curves of DFS and OS in the IC + CTX/NTZ groups were always above the curves in the IC alone group, indicating that IC + CTX/NTZ may still be better than IC alone although the difference was not significant. A main reason responsible for this is the small sample size which was not statistically powerful to detect the difference. Therefore, future study with larger sample is needed to validate these results.

Overall, grade 3-4 toxic events were more common in the IC + CTX/NTZ group than in the IC alone group, and significant differences mainly occurred in anti-EGFR therapy-related toxicities like skin reactions and mucositis. However, the incidence of severe skin and mucositis in our study was significantly less compared with the results in previous studies. Undoubtedly, CTX/NTZ aggravated radiation-induced skin and oral mucositis. Another reason may be that the total dose used in the induction phase is less than that used in concurrent phase. Notably, personal compliance to CTX and NTZ may produce different survival outcomes or different compliance to concurrent chemotherapy. From these considerations, the appropriate dosage and administration way should be further addressed.

Compared with previous studies focusing on the concurrent phase, our study had 2 advantages. First, patients experienced significantly less anti-EGFR therapy-related severe toxicities during radiotherapy, which could result in better tolerance of chemoradiation. Second, cycles of CTX/NTZ used during the induction phase are
usually less than that in the concurrent phase. Hence, the cost of anti-EGFR therapy is also less.

However, limitations of this study should also be acknowledged. Our study is retrospective and the sample size may be small, meaning that potential bias exists. By employing the PSM method to balance various factors varying from pre-treatment staging workup to chemotherapy intensity, we reduced the potential bias as much as we could. Moreover, the follow-up duration may be insufficient. Therefore, we set DFS as the first endpoint to address this. Notably, the dosage of CTX/NTZ used in our study was less than the standard dosage because we had little published evidence regarding the dosage used concurrently with IC. Undoubtedly, further studies are needed to establish the best regimen and dosage. Furthermore, the cycles of IC were not uniform. In light of previous evidence, we recruited patients receiving at least 2 cycles because 2 cycles were sufficient to achieve therapeutic gain. Importantly, we balanced this factor between the 2 groups.

In summary, CTX/NTZ in combination with IC may be a more effective and promising treatment strategy than IC alone in reducing treatment failure and improving overall survival for patients with LA-NPC in the era of IMRT. Our study provides new insight into the

### Table 2

Multivariate regression analysis for prognostic factors

| Variable                      | HR      | 95% CI      | P-value* |
|-------------------------------|---------|-------------|----------|
| Disease-free survival         |         |             |          |
| IC regimen (PF vs TPF)        | 1.728   | 1.118-2.669 | .014     |
| IC regimen (TP vs TPF)        | 1.583   | 1.022-2.451 | .04      |
| N category (N2-3 vs N0-1)     | 2.139   | 1.403-3.260 | <.001    |
| Overall stage (IV vs III)     | 2.040   | 1.415-2.941 | <.001    |
| Treatment group (IC vs IC+CTX/NTZ) | 1.497   | 1.016-2.206 | .041     |
| Overall survival              |         |             |          |
| Gender (female vs male)       | 0.504   | 0.260-0.977 | .043     |
| LDH (>245 vs ≤245 U/L)        | 1.829   | 1.059-3.159 | .03      |
| N category (N2-3 vs N0-1)     | 3.073   | 1.695-5.570 | <.001    |
| Overall stage (IV vs III)     | 2.113   | 1.318-3.837 | .002     |
| Treatment group (IC vs IC+CTX/NTZ) | 1.984   | 1.023-3.848 | .043     |
| Distant metastasis-free survival |     |             |          |
| N category (N2-3 vs N0-1)     | 2.939   | 1.655-5.218 | <.001    |
| Overall stage (IV vs III)     | 2.071   | 1.306-3.284 | .002     |
| Treatment group (IC vs IC+CTX/NTZ) | 1.198   | 0.716-2.005 | .491     |
| Locoregional relapse-free survival | |             |          |
| N category (N2-3 vs N0-1)     | 1.977   | 1.086-3.597 | .026     |
| Overall stage (IV vs III)     | 1.867   | 1.092-3.194 | .023     |
| Treatment group (IC vs IC+CTX/NTZ) | 1.454   | 0.773-2.735 | .246     |

CI, confidence interval; CTX, cetuximab; HR, hazard ratio; IC, induction chemotherapy; LDH, lactate dehydrogenase; NTZ, nimotuzumab; PF, cisplatin with fluorouracil; TP, docetaxel with cisplatin; TPF, docetaxel plus cisplatin with fluorouracil.

*Multivariate P-values were calculated using a Cox proportional hazard regression model with backward elimination for the following prognostic factors: gender (female vs male), age (>43 vs ≤43 y), smoking (yes vs no), drinking (yes vs no), family history of cancer (yes vs no), LDH (>245 vs ≤245 U/L), IC regimen (PF vs TPF, TP vs TPF), cumulative cisplatin dose (≥200 vs <200 mg/m2), T category (T3-4 vs T1-2), N category (N2-3 vs N0-1), overall stage (IV vs III) and treatment group (IC vs IC+CTX/NTZ).

### Table 3

Acute toxicity profile during induction chemotherapy

| Toxity                   | IC + CTX/NTZ (N = 149, %) | IC (N = 447, %) | P-value* |
|--------------------------|---------------------------|-----------------|----------|
| Any                      |                           |                 |          |
| G0-2                     | 71 (47.7)                 | 256 (57.3)      | .041     |
| G3-4                     | 78 (52.3)                 | 191 (42.7)      |          |
| Hematological            |                           |                 |          |
| Neutropenia              |                           |                 |          |
| G0-2                     | 88 (59.0)                 | 289 (64.7)      | .220     |
| G3-4                     | 61 (41.0)                 | 158 (35.3)      |          |
| Anemia                   |                           |                 |          |
| G0-2                     | 147 (98.7)                | 439 (98.2)      | .706     |
| G3-4                     | 2 (1.3)                   | 8 (1.8)         |          |
| Thrombocytopenia         |                           |                 |          |
| G0-2                     | 144 (96.6)                | 440 (98.4)      | .178     |
| G3-4                     | 5 (3.4)                   | 7 (1.6)         |          |
| Non-hematological        |                           |                 |          |
| Liver function           |                           |                 |          |
| G0-2                     | 146 (98.0)                | 439 (98.2)      | .862     |
| G3-4                     | 3 (2.0)                   | 8 (1.8)         |          |
| Renal function           |                           |                 |          |
| G0-2                     | 126 (84.6)                | 445 (99.6)      | <.001    |
| G3-4                     | 23 (15.4)                 | 2 (0.4)         |          |
| Skin reaction            |                           |                 |          |
| G0-2                     | 134 (89.9)                | 435 (97.3)      | <.001    |
| G3-4                     | 15 (10.1)                 | 12 (2.7)        |          |
| Mucositis                |                           |                 |          |
| G0-2                     | 146 (98.0)                | 439 (98.2)      | .861     |
| G3-4                     | 3 (2.0)                   | 8 (1.8)         |          |
| Vomiting                 |                           |                 |          |
| G0-2                     | 141 (94.6)                | 422 (94.4)      | .918     |
| G3-4                     | 8 (5.4)                   | 25 (5.6)        |          |
| Diarrhea                 |                           |                 |          |
| G0-2                     | 146 (98.0)                | 440 (98.4)      | .718     |
| G3-4                     | 3 (2.0)                   | 7 (1.6)         |          |

CTX, cetuximab; IC, induction chemotherapy; NTZ, nimotuzumab.

*P-values were calculated by chi-squared-test or Fisher’s exact test.
usage of targeted therapy in NPC, although these findings need to be validated in prospective studies.

ACKNOWLEDGMENTS

We thank Dr Wei Liang and Dr Lei Shi (YiduCloud Technology, Beijing, China) for kindly providing technical support in searching data on the big-data intelligence platform. We are grateful to Sun Yat-sen University Cancer Center for providing the platform to deposit the study data (RDDA2017000407, available from http://www.researchdata.org.cn/).

CONFLICT OF INTEREST

The authors have no conflict of interest to declare.

ORCID

Ying Sun http://orcid.org/0000-0002-5888-2929
Jun Ma http://orcid.org/0000-0002-1137-9349

REFERENCES

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87-108.
2. Yi JL, Gao L, Huang XD, et al. Nasopharyngeal carcinoma treated by radical radiotherapy alone: ten-year experience of a single institution. Int J Radiat Oncol Biol Phys. 2006;65:161-168.
3. Mao YP, Xie FY, Liu LZ, et al. Re-evaluation of 6th edition of AJCC staging system for nasopharyngeal carcinoma and proposed improvement based on magnetic resonance imaging. Int J Radiat Oncol Biol Phys. 2009;73:1326-1334.
4. Lai SZ, Li WF, Chen L, et al. How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients? Int J Radiat Oncol Biol Phys. 2011;80:661-668.
5. Zhang H, Berezov A, Wang Q, et al. ErBB receptors: from oncogene to targeted cancer therapies. J Clin Invest. 2007;117:2051-2058.
6. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res. 2001;7:2958-2970.
7. Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol. 2002;20:15-135.
8. Ma BB, Poon TC, To KF, et al. Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma-A prospective study. Head Neck. 2003;25:864-872.
9. He X, Xu J, Guo W, Jiang X, Wang X, Zong D. Cetuximab in combination with chemoradiation after induction chemotherapy of locoregionally advanced nasopharyngeal carcinoma: preliminary results. Future Oncol. 2013;9:1459-1467.
10. Li Y, Chen QY, Tang LQ, et al. Concurrent chemoradiotherapy with or without cetuximab for stage II to IVb nasopharyngeal carcinoma: a case-control study. BMC Cancer. 2017;17:567.
11. Xia WX, Liang H, Lv X, et al. Combining cetuximab with chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma: a propensity score analysis. Oral Oncol. 2017;67:167-174.
12. Xu T, Liu Y, Dou S, Li F, Guan X, Zhu G. Weekly cetuximab concurrent with IMRT aggravated radiation-induced oral mucositis in locally advanced nasopharyngeal carcinoma: results of a randomized phase II study. Oral Oncol. 2015;51:875-879.
13. You R, Hua YJ, Liu YP, et al. Concurrent chemoradiotherapy with or without anti-EGFR-targeted treatment for stage II-IVb nasopharyngeal carcinoma: retrospective analysis with a large cohort and long follow-up. Theranostics. 2017;7:2314-2324.
14. You R, Sun R, Hua YJ, et al. Cetuximab or nimotuzumab plus intensity-modulated radiotherapy versus cisplatin plus intensity-modulated radiotherapy for stage II-IVb nasopharyngeal carcinoma. Int J Cancer. 2017;141:1265-1276.
15. Huang JF, Zhang FZ, Zou QZ, et al. Induction chemotherapy followed by concurrent chemoradiation and nimotuzumab for locoregionally advanced nasopharyngeal carcinoma: preliminary results from a phase II clinical trial. Oncotarget. 2017;8:2457-2465.
16. Cao SM, Yang Q, Guo L, et al. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase III multicentre randomised controlled trial. Eur J Cancer. 2017;75:14-23.
17. Hui EP, Ma BB, Leung SF, et al. Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol. 2009;27:242-249.
18. Peng H, Chen L, Zhang J, et al. Induction chemotherapy improved long-term outcomes of patients with locoregionally advanced nasopharyngeal carcinoma: a propensity matched analysis of 5-year survival outcomes in the era of intensity-modulated radiotherapy. J Cancer. 2017;8:371-377.
19. Sun Y, Li WF, Chen NY, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol. 2016;17:1509-1520.
20. Kawahira M, Yokota T, Hamauchi S, et al. Survival benefit of adding docetaxel, cisplatin, and 5-fluorouracil induction chemotherapy to concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma with nodal Stage N2-3. Jpn J Clin Oncol. 2017;47:705-712.
21. Lv JW, Chen YP, Huang XD, et al. Hepatitis B virus screening and reactivation and management of patients with nasopharyngeal carcinoma: a large-scale, big-data intelligence platform-based analysis from an endemic area. Cancer. 2017;123:3540-3549.
22. Peng H, Chen L, Li WF, et al. Optimize the cycle of neoadjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma treated with intensity-modulated radiotherapy: a propensity score matching analysis. Oral Oncol. 2016;62:78-84.
23. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
24. Austin PC. The relative ability of different propensity score methods to balance measured covariates between treated and untreated subjects in observational studies. Med Decis Making. 2009;29:661-677.
25. Sun X, Su S, Chen C, et al. Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities. Radiother Oncol. 2014;110:398-403.
26. Lin JC, Liang WM, Jan JS, Jiang RS, Lin AC. Another way to estimate outcome of advanced nasopharyngeal carcinoma—is concurrent chemoradiotherapy adequate? Int J Radiat Oncol Biol Phys. 2004;60:156-164.
27. Chan AT, Hsu MM, Goh BC, et al. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. *J Clin Oncol*. 2005;23:3568-3576.

28. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. *N Engl J Med*. 2004;351:337-345.

29. Pfister DG, Su YB, Kraus DH, et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. *J Clin Oncol*. 2006;24:1072-1078.

30. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. *N Engl J Med*. 2008;359:1116-1127.

**SUPPORTING INFORMATION**

Additional Supporting Information may be found online in the supporting information tab for this article.

**How to cite this article:** Peng H, Tang L-L, Liu X, et al. Anti-epidermal growth factor receptor therapy concurrently with induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma. *Cancer Sci*. 2018;109:1609-1616. https://doi.org/10.1111/cas.13589